Redcliffe Partners advised CVC on obtaining merger clearance from the Ukrainian competition authority for its acquisition of Recordati S.p.A. (Recordati). The deal is valued at approximately EUR 3 billion. Through its expertise and global healthcare network CVC will expand Recordati’s rare disease business and accelerate its growth strategy as a leading global company in the pharmaceutical industry.
* * *
CVC is a world leader in private equity and comprises 24 offices globally, making it one of the most geographically diverse and longest established networks of any private equity investor worldwide.
Recordati is an international pharmaceutical group, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. The Recordati Group offers a wide range of innovative pharmaceuticals in a number of therapeutic areas including a specialised segment dedicated to treatments for rare diseases.